Johnson Pharmacare Reports Wider Net Loss in Q1 FY2026, Expenses Rise
Johnson Pharmacare Limited reported a net loss of Rs. 5.34 lacs for Q1 FY2026, compared to Rs. 3.99 lacs in Q1 FY2025. The company had no revenue from operations, while total expenses increased to Rs. 5.34 lacs from Rs. 3.99 lacs year-over-year. Other expenses rose to Rs. 5.04 lacs, and employee benefit expenses were Rs. 0.30 lacs. The company's paid-up equity share capital remains at Rs. 5,500 lacs. The Board of Directors approved these unaudited results on July 23, 2025, after review by the Audit Committee and limited review by statutory auditors.
01Apr 25
Johnson & Johnson's Talc Claims Bankruptcy Plan Rejected for Third Time
Johnson & Johnson's $9 billion trust fund proposal to settle talc-related cancer claims through bankruptcy has been rejected by a federal judge due to flawed voting procedures. This dismissal, the third such attempt, potentially exposes J&J to continued lawsuits in the traditional court system. The decision could lead to increased legal costs, prolonged financial uncertainty, and possible reputational damage for the company as it faces thousands of talc-related lawsuits alleging its products caused cancer.
12Mar 25
Johnson & Johnson Secures ₹3.34 Crore Victory in Delhi High Court Counterfeit Case
Johnson & Johnson has won a significant legal battle against counterfeit medical products in India. The Delhi High Court awarded J&J ₹3.34 crore in damages and issued a permanent injunction against the defendants for manufacturing and selling fake surgical products under J&J's trademarks. The court emphasized the public health risks posed by counterfeit medical products. This ruling reinforces J&J's brand protection efforts, commitment to patient safety, and sends a strong message to counterfeiters in the healthcare industry.
19Feb 25
Johnson & Johnson Faces Crucial Moment in $9 Billion Baby Powder Settlement
Johnson & Johnson is seeking approval for a $9 billion settlement to resolve lawsuits claiming its baby powder caused cancer. A lawyer representing 20,000 women is urging the court to approve the settlement. J&J's use of Chapter 11 bankruptcy strategy has faced opposition, including from the U.S. Trustee. The pre-bankruptcy voting process has also been questioned. If approved, this would be one of the largest mass tort litigation settlements in U.S. history, potentially allowing J&J to move past the controversy.